Efficacy of Anti-Leishmania Therapy in Visceral Leishmaniasis among HIV Infected Patients: A Systematic Review with Indirect Comparison

PLoS Neglected Tropical Diseases

Volumn 7, Issue 5, 2013, Pages

  Cota, Gláucia F ^a,b   de Sousa, Marcos R ^c   Fereguetti, Tatiani Oliveira ^b   Rabello, Ana ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FUNDAÇÃO HOSPITALAR DO ESTADO DE MINAS GERAIS   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; MEGLUMINE; MILTEFOSINE; STIBOGLUCONATE SODIUM;

ANEMIA; BLEEDING; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; HEART DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; KIDNEY DISEASE; LIVER DISEASE; META ANALYSIS (TOPIC); MORTALITY; MULTICENTER STUDY (TOPIC); PANCREAS DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS; VOMITING;

EID: 84878484762     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002195     Document Type: Review

References (42)

1. Alvar J, Aparicio P, Aseffa A, Den Boer M, Canavate C, et al. (2008) The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 21 (2): 334-359.
2. Murray HW, (2010) Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India. Future Microbiol 5 (9): 1301-1303.
3. Murray HW, (2004) Treatment of visceral leishmaniasis in 2004. Am J Trop Med Hyg 71 (6): 787-794.
4. Paredes R, Munoz J, Diaz I, Domingo P, Gurgui M, et al. (2003) Leishmaniasis in HIV infection. J Postgrad Med 49 (1): 39-49.
5. Cota GF, de Sousa MR, Rabello A, (2011) Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS Negl Trop Dis 5 (6): e1153.
6. Ritmeijer K, Veeken H, Melaku Y, Leal G, Amsalu R, et al. (2001) Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans R Soc Trop Med Hyg 95 (6): 668-672.
7. Paredes R, Laguna F, Clotet B, (1997) Leishmaniasis in HIV-infected persons: a review. J Int Assoc Physicians AIDS Care 3 (6): 22-39.
8. Moore EM, Lockwood DN, (2010) Treatment of visceral leishmaniasis. J Glob Infect Dis 2 (2): 151-158.
9. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, et al. (2005) Indirect comparisons of competing interventions. Health Technol Assess 9 (26): 1-134, iii-iv.
10. Gartlehner G, Moore CG, (2008) Direct versus indirect comparisons: a summary of the evidence. Int J Technol Assess Health Care 24 (2): 170-177.
11. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6 (7): e1000100.
12. Higgins JPT, Green S (2011). Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration. Available: www.cochrane-handbook.org. Accessed 2 September 2012.
13. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, et al. (2011) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. Available: www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 25 November 2012.
14. Sterne JA, Gavaghan D, Egger M, (2000) Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 53 (11): 1119-1129.
15. Ribera E, Cucurull E, Ocana I, Vallespi T, Gasser I, et al. (1995) Visceral leishmaniasis in patients with HIV infection. Enferm Infecc Microbiol Clin 13 (2): 73-79.
16. Ribera E, Ocana I, de Otero J, Cortes E, Gasser I, et al. (1996) Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Am J Med 100 (5): 496-501.
17. Laguna F, Adrados M, Alvar J, Soriano V, Valencia ME, et al. (1997) Visceral leishmaniasis in patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis 16 (12): 898-903.
18. Montalban C, Calleja JL, Erice A, Laguna F, Clotet B, et al. (1990) Visceral leishmaniasis in patients infected with human immunodeficiency virus. Co-operative Group for the Study of Leishmaniasis in AIDS. J Infect 21 (3): 261-270.
19. Russo R, Nigro LC, Minniti S, Montineri A, Gradoni L, et al. (1996) Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). The Journal of infection 32 (2): 133-137.
20. Lopez-Velez R, Turientes MC, Gomez-Mampaso E, (1998) Serologic cross-reactions to Leishmania infantum using indirect immunofluorescence in HIV+ and HIV- patients with active tuberculosis. Enferm Infecc Microbiol Clin 6 (3): 130-131.
21. Berhe N, Wolday D, Hailu A, Abraham Y, Ali A, et al. (1999) HIV viral load and response to antileishmanial chemotherapy in co-infected patients. AIDS 13 (14): 1921-1925.
22. Laguna F, (2003) Treatment of leishmaniasis in HIV-positive patients. Ann Trop Med Parasitol 97: 135-142.
23. Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, et al. (2006) A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis 43 (3): 357-364.
24. Molina I, Falco V, Crespo M, Riera C, Ribera E, et al. (2007) Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 60 (4): 837-842.
25. Sinha PK, van Griensven J, Pandey K, Kumar N, Verma N, et al. (2011) Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India. Clin Infect Dis 53 (7): e91-8.
26. Ritmeijer K, ter Horst R, Chane S, Aderie EM, Piening T, et al. (2011) Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. Clin Infect Dis 53 (12): e152-158.
27. Laguna F, Lopez-Velez R, Pulido F, Salas A, Torre-Cisneros J, et al. (1999) Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS 13 (9): 1063-1069.
28. Delgado J, Macias J, Pineda JA, Corzo JE, Gonzalez-Moreno MP, et al. (1999) High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. Am J Trop Med Hyg 61 (5): 766-769.
29. Delgado FM, Garcia OMA, Martos PF, Reguera IJM, Jimenez OF, et al. (1997) The clinical and evolutional characteristics of visceral leishmaniasis in patients with HIV infection. Ann Med Interne 14 (10): 506-510.
30. Rosenthal E, Marty P, Poizot-Martin I, Reynes J, Pratlong F, et al. (1995) Visceral leishmaniasis and HIV-1 co-infection in southern France. Trans R Soc Trop Med Hyg 89 (2): 159-162.
31. Pintado V, Martin-Rabadan P, Rivera ML, Moreno S, Bouza E, (2001) Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine 80 (1): 54-73.
32. Pintado V, Lopez-Velez R, (2001) HIV-associated visceral leishmaniasis. Clin Microbiol Infect 7 (6): 291-300.
33. den Boer M, Davidson RN, (2006) Treatment options for visceral leishmaniasis. Expert Rev Anti Infect Ther 4 (2): 187-197.
34. Frezard F, Demicheli C, Ribeiro RR, (2009) Pentavalent antimonials: new perspectives for old drugs. Molecules 14 (7): 2317-2336.
35. Croft SL, Yardley V, (2002) Chemotherapy of leishmaniasis (2002) Curr Pharm Des 8 (4): 319-342.
36. Bern C (2012) Treatment of visceral leishmaniasis. UpToDate, Inc. Wolters Kluwer Health. Available: http://www.uptodate.com/contents/treatment-of-visceral-leishmaniasis. Accessed 2 November 2012.
37. Herwaldt BL, Berman JD, (1992) Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. The Am J Trop Med Hyg 46 (3): 296-306.
38. Adler-Moore J, Proffitt RT, (2002) AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 49 (1): 21-30.
39. Balasegaram M, Ritmeijer K, Lima MA, Burza S, Genovese GO, et al. (2012) Liposomal amphotericin B as a treatment for human leishmaniasis. Expert Opin Emerg Drugs 17 (4): 493-510.
40. Donegan S, Williamson P, Gamble C, Tudur-Smith C, (2010) Indirect comparisons: a review of reporting and methodological quality. PloS One 5 (11): e11054.
41. Song F, Altman DG, Glenny AM, Deeks JJ, (2003) Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 326 (7387): 472.
42. Song F, Xiong T, Parekh-Bhurke S, Loke YK, Sutton AJ, et al. (2011) Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study. BMJ 343: d4909.